Onapgo Injection, Solution
NDC Package 27505-006-05

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Onapgo (apomorphine hydrochloride) injection is oNAPGO is indicated for the treatment of motor fluctuations in adults with advanced Parkinson's disease. This formulation utilizes a injection, solution delivery system. Marketed by Mdd Us Operations, Llc, A Subsidiary Of Supernus Pharmaceuticals, Inc, this product is identified by NDC 27505-006 and is authorized under FDA application NDA214056.

Identification & Billing

NDC Package Code
27505-006-05
Package Description
5 CARTRIDGE in 1 CARTON / 20 mL in 1 CARTRIDGE (27505-006-01)
Product Code
27505-006
11-Digit Billing Format
27505000605
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Onapgo
Non-Proprietary Name
Apomorphine Hydrochloride
Substance Name
Apomorphine Hydrochloride
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
APOMORPHINE HYDROCHLORIDE 4.9 mg/mL
Pharmacologic Class
Usage Information
ONAPGO is indicated for the treatment of motor fluctuations in adults with advanced Parkinson's disease.

Regulatory & Marketing

Labeler Name
Mdd Us Operations, Llc, A Subsidiary Of Supernus Pharmaceuticals, Inc
Product Type
Human Prescription Drug
FDA Application #
NDA214056
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
02-04-2025
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 27505-006-05 identifies a specific commercial package of 5 cartridge in 1 carton / 20 ml in 1 cartridge (27505-006-01) of Onapgo, a human prescription drug labeled by Mdd Us Operations, Llc, A Subsidiary Of Supernus Pharmaceuticals, Inc. This injection, solution is formulated for subcutaneous use and contains apomorphine hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Mdd Us Operations, Llc, A Subsidiary Of Supernus Pharmaceuticals, Inc on February 04, 2025. The current certification is valid through December 31, 2027.

How is this Mdd Us Operations, Llc, A Subsidiary Of Supernus Pharmaceuticals, Inc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 27505000605. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
27505-006-05
11-Digit CMS (5-4-2)
27505-0006-05

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.